Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560843 | 0.89 | MAPT (0.42) | MAPTSMN1; SMN2HRH4MEN1KMT2A | |
| SCHEMBL6562222 | 0.86 | MAPT (0.47) | MAPTSMN1; SMN2HRH4MEN1KMT2A | |
| SCHEMBL6562673 | 0.85 | MAPT (0.58) | MAPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6560540 | 0.84 | NPC1 (0.59) | MAPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6562758 | 0.82 | MAPT (0.44) | MAPTSMN1; SMN2HRH4MEN1KMT2A | |
| SCHEMBL6560420 | 0.82 | KDM4E (0.47) | MAPTSMN1; SMN2HRH4MEN1KMT2A | |
| SCHEMBL7804724 | 0.82 | PDGFRB (0.39) | MAPTSMN1; SMN2MAPK1HTTNPSR1 | |
| SCHEMBL6560436 | 0.80 | MAPT (0.48) | MAPTSMN1; SMN2HRH4MEN1KMT2A | |
| SCHEMBL6559804 | 0.79 | MAPT (0.47) | MAPTSMN1; SMN2KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6561340 | 0.79 | HTR1A (0.46) | MAPTSMN1; SMN2HRH4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1075469-B1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | MAPT 4877/4885SMN1; SMN2 2466/4885HRH4 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.